产品封面图

pCMV-VSV-G载体

收藏
  • ¥1250
  • ZYbscience
  • 中国/美国
  • ZY8454
  • 2025年07月13日
    avatar
    上海泽叶生物科技有限公司
    11 年钻石会员

  • 企业认证

    点击 QQ 联系

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 保存条件：

      -20℃低温保存

    • 保质期：

      三年

    • 英文名：

      pCMV-VSV-G

    • 库存：

      20

    • 供应商：

      泽叶生物

    载体基本信息

    出品公司: ZYbscience
    试剂名称: pCMV-VSV-G
    质粒类型: 哺乳动物载体；逆病毒包装；双质粒包装系统；信封载体
    高拷贝/低拷贝: 高拷贝
    克隆方法: 限制性内切酶，多克隆位点
    启动子: CMV
    载体大小: 6507 bp
    5' 测序引物及序列: CMV fwd 5’CGCAAATGGGCGGTAGGCGTG 3’
    3' 测序引物及序列: --
    载体标签: 无
    载体抗性: Ampicillin
    筛选标记: 无
    克隆菌株: DH5α等
    宿主细胞（系）: 包装细胞系如293T
    备注: 逆病毒包装载体pCMV-VSV-G需要与pUMVC共同使用，使用方法见下文。
    产品目录号: ZY8454
    稳定性: 瞬表达
    组成型/诱导型: 组成型
    病毒/非病毒: 非病毒

    载体质粒图谱和多克隆位点信息

    pCMV-VSV-G载体图谱


    载体简介

    双质粒系统逆病毒包装质粒pCMV-VSV-G使用方法

Day 1

1.      Plate 5 x 105 293T cells in 6 cm2 dishes containing 5 mL of media. (This can be scaled up if desired)


Day 2

1.      Set up (use polypropylene tubes for this; polystyrene tubes DO NOT work!):

           1 µg retroviral DNA encoding gene X
           1 µg packaging plasmid Mix
                the packaging plasmid (pUMVC3) at a 8:1 ratio with the envelope plasmid (pCVM-VSV-G)-a total of 1µg
           DME without serum to 94μL total
           6 μL Fugene

       Mix and wait 15 to 30 minutes at room temperature

       Add to 293T cells without touching the sides of the dish (DO NOT CHANGE MEDIA)

       If you are using amphotropic virus then move immediately to BL2+ in a secondary container, which has an absorbent material. 

       (This does not mean a couple of hours; it means Immediately!).  The rest of this protocol is the same for all viruses---the BL2+ safety practices are in place if you are using amphotropic viruses 


Day 3

1.      Change the media to whatever media you wish to use when infecting target cells. 293T cells are easily detached so remember not to put the media directly onto to cells, but rather “run” it down the side of the dish. Remember that you will get the highest titer virus when your cells are “happy.”

2.      Plate out your target cells


Day 4

1.      Remove the medium from the 293T cells and use a 0.45 u syringe filter to remove any 293T cells. DO NOT use the 0.2 u filter, as it is likely to shear the envelope from your virus
making it noninfectious

        Note: After filtering, the filter should be removed and placed in the biohazard bag in the hood and the syringe rinsed with bleach and decontaminated for a minimum of 20 min. It is useful to place a plastic beaker with bleach in the hood in advance

2.      Add 8 to 10 μg/ml of polybrene (Hexadimethrine bromide) or protamine sulfate to the target cells

3.      Carry out infection for 1 to 4 hours. Remove virus and replace with fresh media

        Note: If you wish to do a second infection the following day, it is important to put fresh media on the cells and not let the virus remain on the cells overnight. The media contains huge amounts of envelope, both associated and unassociated with viral particles, which will bind all the cell surface receptors required for virus adsorption, resulting in their down-regulation. Hence, if you don’t change the media after the initial infection, very few receptors will be available for the next round of infection. In addition, very few cells tolerate the presence of high levels of the VSV-G envelope for extended periods of time (i.e. a lot of your cells may die)


Day 5 +

1.      Allow the cells to recover and begin to express the virus-encoded genes. The cells usually require 48 hours for this to occur

2.      Add drug if you are scoring for the presence of a vector that carries a drug resistance marker. Prior to this step it is advisable that you titrate the drug to be used for selection in order to know precisely how much to add. In addition, it is necessary to bring an extra plate of uninfected cells (often referred to as “canaries”) which will function as a positive control in the kill assay.  Add drug to both plates. When your canaries are dead, you can remove the drug.

    载体序列

    Please note that depositor's sequence is not 100% complete. The flanking sequence of VSV-G actually contains XhoI (at both the 5' and 3'end).

LOCUS       pCMV-VSV-G Sequencing Result	6507 bp 	DNA	SYN
DEFINITION  pCMV-VSV-G Sequencing Result
ACCESSION   
KEYWORDS    
SOURCE      
  ORGANISM  other sequences; artificial sequences; vectors.
FEATURES             Location/Qualifiers
     source          1..6507
                     /organism="pCMV-VSV-G Sequencing Result"
                     /mol_type="other DNA"
     promoter        84..660
                     /label="CMV_immearly_promoter"
     misc_feature    148..974
                     /label="5_LTR"
     misc_feature    163..450
                     /label="CAG_enhancer"
     misc_feature    617..637
                     /label="CMV_fwd_primer"
     promoter        618..687
                     /label="CMV_promoter"
     promoter        630..749
                     /label="CMV2_promoter"
     misc_feature    661..680
                     /label="pCEP_fwd_primer"
     misc_feature    663..687
                     /label="LNCX_primer"
     misc_feature    778..1350
                     /label="bGlob_int"
     CDS             1322..2971
                     /label="ORF frame 2"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     gene            1436..2959
                     /label="vsv-G"
                     /gene="vsv-G"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     misc_feature    2936..2968
                     /label="VSVG Tag"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     terminator      3118..3644
                     /label="rb_glob_PA_terminator"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     misc_feature    complement(3689..3711)
                     /label="M13_pUC_rev_primer"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     promoter        complement(3725..3754)
                     /label="lac_promoter"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     gene            complement(4837..5697)
                     /label="Ampicillin"
                     /gene="Ampicillin"
                     /translation="MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRNSDTMKCLLY
                     LAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKS
                     HKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLN
                     PGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNS
                     TTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQ
                     YCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILD
                     YSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAP
                     ILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL
                     HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFF
                     IIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK*"
     CDS             complement(4837..5697)
                     /label="ORF frame 1"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     promoter        complement(5739..5767)
                     /label="AmpR_promoter"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     misc_feature    complement(6284..6439)
                     /label="lacZ_a"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     misc_feature    6410..6432
                     /label="M13_pUC_fwd_primer"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     promoter        6425..6441
                     /label="M13_forward20_primer"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     promoter        6451..6469
                     /label="T7_promoter"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
ORIGIN

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验

    • 【求助】转染后有mRNA没有蛋白表达

      birkin 我在尝试转染某种细胞，载体是购买的商业载体（pCMV6)，之前转染HEK293作为预实验，已经用WB证明有效，但是换到现在这种细胞之后就很奇怪，一开始想用短期转，结果WB做不出来，觉得可能是转染率太低，于是又改做稳定转染，用了G418筛选。花了近2个月，细胞稳定下来了，取样做RT-PCR，有相当强的mRNA表达（-RT和对照组转染也做了的，基本没有带，所以不会是污染），谁知做WB还是一点东西都没有……我都快疯了，既然能抗G418，又有大量mRNA

    • Hematopoietic Stem Cell Targeting with Surface-Engineered Lentiviral Vectors

      construct with 8.6 µg of the lentiviral gene-transfer vector and the two glycoproteins: VSV-G (1.5 µg) and TPOHA (1.5 µg) or VSV-G (1.5 µg) and SCFSUx (1.5 µg). Cotransfect TPOHA with the neuraminidase-expressing plasmid (pCMV-NA) to allow

    • 多重PCR同时检测口蹄疫病毒、猪水疱病病毒和水疱性口炎病毒

      45 s，30个循环；72 ℃延伸10 min。取10 μL PCR产物在20 g/L琼脂糖凝胶电泳检测。 1.7 多重PCR扩增 分别将上述1.5合成的FMDV，SVDV和VSV cDNA产物作为模板，在同一管内同时加入3对引物进行PCR扩增。反应条件及PCR反应参数如上1.6。PCR扩增结束后取10 μL扩增产物于20 g/L的琼脂糖凝胶（含0.5 μg/ mL溴化乙锭）中电泳检测。  

    查看更多相关实验 >
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    载体pCMV-VSV-G
    ¥800
    上海沪震实业有限公司
    2025年07月12日询价
    pCMV-VSV-G载体
    ¥1000
    上海再康生物科技有限公司
    2025年11月21日询价
    pCMV-VSV-G载体
    ￥1000
    上海盖宁生物科技有限公司
    2025年12月22日询价
    pCMV-VSV-G载体
    ¥1000
    上海信裕生物科技有限公司
    2025年07月12日询价
    VSV-G载体
    ¥1650
    上海泽叶生物科技有限公司
    2025年07月10日询价
    pCMV-VSV-G载体
    ¥1250